Company description::
AlphaRx Received C$485,000 order on Flexogan from Shoppers Drug Mart - AlphaRx Targets Large Market Opportunities
THURSDAY , JANUARY 29, 2004 08:36 AM
RICHMOND HILL, ON, Jan 29, 2004 (Canada NewsWire via COMTEX) -- AlphaRx Inc. (OTCBB: ALRX) is pleased to announce that it has received orders in excess of C$485,000 for its Flexogan(TM) product from Shoppers Drug Mart, Canada's largest drug store chain.
"This confirms and validates the potential for Flexogan(TM) as it has now achieved full national distribution coverage in Canada. It also illustrates the Company's ability to take a concept from development to market" said Michael Lee, President of AlphaRx. "We have built a successful business model and we are ready to launch a line of profoundly effective OTC anti-acne products and expand our Flexogan(TM) sales into the United States."
About Flexogan
Flexogan(TM) is a series of over-the-counter pain relief products incorporating AlphaRx's proprietary BCD(TM) (Bioadhesive Colloidal Dispersion) advanced drug delivery technology. Independent research confirms Flexogan(TM) formulations suppress induced inflammation as much as 300% more effectively than current best selling North American topical pain relief products. For more information, please visit www.flexogan.com.
About AlphaRx Inc.
AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. AlphaRx's broad product pipeline consists of drugs with a strong commercial potential that can be dramatically improved through the application of its proprietary BCD(TM) drug delivery technology. For more information, please visit www.alpharx.com.
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=32193
|
